专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08216614B2 Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis 有权
标题翻译：柠檬酸钾粉末混合用于治疗肾结石和骨质疏松症
公开(公告)号：US08216614B2
公开(公告)日：2012-07-10
申请号：US12784305
申请日：2010-05-20
申请人： Charles Y. C. Pak , Khashayar Sakhaee , Neill B. Walsdorf, Sr.
发明人： Charles Y. C. Pak , Khashayar Sakhaee , Neill B. Walsdorf, Sr.
IPC分类号： A61K33/24 , A61K33/06 , A61K33/10 , A61K33/08 , A61K31/19
CPC分类号： A61K33/08 , A61K31/19 , A61K33/10 , A61K2300/00
摘要： A composition comprising a powder mixture of potassium citrate and calcium citrate as mixtures of pure chemical salts and methods of making and using the composition are disclosed. The composition is useful for the treatment and prevention of kidney stones and osteoporosis and better delivers potassium and calcium than commonly used potassium and calcium supplements.
摘要翻译：公开了一种组合物，其包含柠檬酸钾和柠檬酸钙作为纯化学盐的混合物的粉末混合物，以及制备和使用该组合物的方法。该组合物可用于治疗和预防肾结石和骨质疏松症，并且比常用的钾和钙补充剂更好地输送钾和钙。

2. 发明申请

US20100227006A1 POWDER MIX OF POTASSIUM CALCIUM CITRATE FOR THE TREATMENT OF KIDNEY STONES AND OSTEOPOROSIS 有权
标题翻译：用于治疗KIDNEY STONES和OSTEOPOROSIS的磷酸钙的粉末混合物
公开(公告)号：US20100227006A1
公开(公告)日：2010-09-09
申请号：US12784305
申请日：2010-05-20
申请人： Charles Y. C. Pak , Khashayar Sakhaee , Neill B. Walsdorf, SR.
发明人： Charles Y. C. Pak , Khashayar Sakhaee , Neill B. Walsdorf, SR.
IPC分类号： A61K33/10 , A61P19/10 , A61K33/08
CPC分类号： A61K33/08 , A61K31/19 , A61K33/10 , A61K2300/00
摘要： A composition comprising a powder mixture of potassium citrate and calcium citrate as mixtures of pure chemical salts and methods of making and using the composition are disclosed. The composition is useful for the treatment and prevention of kidney stones and osteoporosis and better delivers potassium and calcium than commonly used potassium and calcium supplements.
摘要翻译：公开了一种组合物，其包含柠檬酸钾和柠檬酸钙作为纯化学盐的混合物的粉末混合物，以及制备和使用该组合物的方法。该组合物可用于治疗和预防肾结石和骨质疏松症，并且比常用的钾和钙补充剂更好地输送钾和钙。

3. 发明授权

US4966776A Compositions and methods of treating calcium renal stones 失效
标题翻译：治疗钙肾结石的组成和方法
公开(公告)号：US4966776A
公开(公告)日：1990-10-30
申请号：US412801
申请日：1989-09-27
申请人： Charles Y. C. Pak
发明人： Charles Y. C. Pak
IPC分类号： A61K31/19
CPC分类号： A61K31/19 , Y10S514/891
摘要： Methods and compositions useful for the treatment and prophylaxis of calcium renal stones in persons with hypocitraturia or undergoing allopurinol therapy are disclosed. The methods involve administering potassium citrate compositions to persons afflicted with or susceptible to calcium renal stone formations. A typical dosage scheme involves administering about 30 to 120 meq potassium citrate per day in divided doses. Such treatments are effective in dissolving existing calcium stones and preventing formation of new calcium stones. Moreover, the results of a comparative clinical assay indicate the potassium citrate is superior to sodium citrate in the treatment of uric acid lithiasis. Potassium citrate therapy averts calcium renal stone formation, a complication which is often associated with sodium citrate or sodium bicarbonate alkalinization therapy.
摘要翻译：公开了用于治疗和预防患有hypoitraturia或正在进行别嘌呤醇治疗的患者中的钙肾结石的方法和组合物。所述方法涉及将柠檬酸钾组合物施用于患有钙敏感性肾结石形成的患者或易受影响的人。典型的剂量方案包括每天以分剂量施用约30至120毫克柠檬酸钾。这种治疗有效地溶解现有的钙结石并防止形成新的钙结石。此外，比较临床检验的结果表明柠檬酸钾在治疗尿酸结石时优于柠檬酸钠。柠檬酸钾治疗可以避免钙肾结石形成，这种并发症通常与柠檬酸钠或碳酸氢钠碱化治疗相关。

4. 发明授权

US4883791A 25S,26-dihydroxycholecalciferol in the treatment of hypercalcitriolemic disease states 失效
标题翻译： 25S，26-二羟基胆钙化醇治疗高钙血症疾病状态
公开(公告)号：US4883791A
公开(公告)日：1989-11-28
申请号：US99191
申请日：1987-09-21
申请人： Charles Y. C. Pak , Milan R. Uskokovic , Joseph E. Zerwekh
发明人： Charles Y. C. Pak , Milan R. Uskokovic , Joseph E. Zerwekh
IPC分类号： A61K31/59
CPC分类号： A61K31/59 , Y10S514/891
摘要： The invention is directed to a method in the treatment of hypercalcitriolemic disease states which comprises administering an effective amount of 25S,26-dihydroxycholecalciferol to a host in need of such treatment.
摘要翻译：本发明涉及治疗高精氨酸症状的方法，其包括将有效量的25S，26-二羟基胆钙化甾醇施用于需要这种治疗的宿主。

5. 发明授权

US07052833B1 Absorptive hypercalciuria locus on human chromosome 1 失效
标题翻译：人类染色体1上的吸收性高钙蛋白基因座
公开(公告)号：US07052833B1
公开(公告)日：2006-05-30
申请号：US09339352
申请日：1999-06-23
申请人： Berenice Y. Reed-Gitomer , Charles Y. C. Pak
发明人： Berenice Y. Reed-Gitomer , Charles Y. C. Pak
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156 , Y10S435/81
摘要： Disclosed is a region on human chromosome 1 that provides a genetic basis for absorptive hypercalciuria. The genes, proteins, and other biological materials provided are envisioned for use in diagnostic and therapeutic methods related to absorptive hypercalciuria and osteoporosis with hypercalciuria.
摘要翻译：公开了人类染色体1上为吸收性高钙尿症提供遗传基础的区域。提供的基因，蛋白质和其他生物材料被设想用于与吸收性高钙尿症和具有高钙尿症的骨质疏松症有关的诊断和治疗方法。

6. 发明授权

US5432200A Method for increasing urinary excretion of electrolytes 失效
标题翻译：增加电解质排泄尿的方法
公开(公告)号：US5432200A
公开(公告)日：1995-07-11
申请号：US46013
申请日：1993-04-12
申请人： Neill B. Walsdorf , George Alexandrides , Charles Y. C. Pak
发明人： Neill B. Walsdorf , George Alexandrides , Charles Y. C. Pak
IPC分类号： A23L1/304 , A61K31/19 , C07C59/265
CPC分类号： A61K31/19 , A23L33/16 , C07C59/265
摘要： A method for supplementing dietary potassium, magnesium and citrate is disclosed that comprises orally administering an effective amount of potassium magnesium citrate in a single salt. Methods for decreasing urinary calcium and oxalate by the administration of potassium magnesium citrate in a single salt are also disclosed.
摘要翻译：公开了一种补充膳食钾，镁和柠檬酸盐的方法，其包括在单一盐中口服施用有效量的柠檬酸钾钾。还公开了通过在单一盐中施用柠檬酸钾钾来降低尿钙和草酸盐的方法。

7. 发明授权

US4921807A Method and apparatus for maintaining urine specimens 失效
标题翻译：维持尿标本的方法和装置
公开(公告)号：US4921807A
公开(公告)日：1990-05-01
申请号：US148148
申请日：1988-01-26
申请人： Charles Y. C. Pak
发明人： Charles Y. C. Pak
IPC分类号： G01N1/28 , G01N33/483
CPC分类号： G01N1/28 , Y10S514/97 , Y10T436/10 , Y10T436/108331 , Y10T436/171538 , Y10T436/201666 , Y10T436/2525
摘要： A urine specimen is preserved from bacterial deterioration as to relative constituents by adding thymol. To the thymol-treated specimen, lithium-solution volume-marker is added, then is divided into two (first and second) separate portions. Thereupon, using the first portion, standard conventional measurements and/or analysis is conducted for total volume, pH/acidity, uric acid, citrate, sodium, and potassium. To the second portion, there is added boric acid and hydrochloric acid, followed by standard/conventional measurement and/or analysis for ammonium ion, citrate, calcium, magnesium, phosphorus, oxalate and sulfate. Thereafter the findings are charted and compared to controls.
摘要翻译：通过添加百里酚，可以保存尿液样本以防止细菌恶化。向经过百里酚处理的样品中加入锂溶液体积标记物，然后分成两个（第一和第二）分离部分。因此，使用第一部分，对总体积，pH /酸度，尿酸，柠檬酸盐，钠和钾进行标准常规测量和/或分析。向第二部分加入硼酸和盐酸，然后进行铵离子，柠檬酸盐，钙，镁，磷，草酸盐和硫酸盐的标准/常规测量和/或分析。此后，结果被绘制并与对照进行比较。

8. 发明授权

US5075499A Calcium supplementation by dicalcium citrate-lactate 失效
标题翻译：钙柠檬酸钙补充钙
公开(公告)号：US5075499A
公开(公告)日：1991-12-24
申请号：US275046
申请日：1988-11-21
申请人： Neill B. Walsdorf , George Alexandrides , Charles Y. C. Pak
发明人： Neill B. Walsdorf , George Alexandrides , Charles Y. C. Pak
IPC分类号： A61K31/19 , C07C59/08 , C07C59/265
CPC分类号： A61K31/19 , C07C59/08 , C07C59/265
摘要： One aspect of the present invention includes the novel compound having the formula:Ca.sub.2 (OOC--CH.sub.2 --COHCOO-CH.sub.2 COO)(CH.sub.3 CHOH-COO)In another aspect of the present invention, a method is provided for the treatment of a calcium related pathology. The inventive method includes the steps of providing a pharmaceutically acceptable composition, including as the active principle the compound dicalcium citrate-lactate, and administering to an individual in need thereof a therapeutically effective amount of said pharmaceutically acceptable composition.In yet another aspect of the present invention, a process is provided for producing the compound dicalcium citrate-lactate. The inventive process comprising the steps of: (a) admixing stoichiometric quantities of citric acid and a calcium compound selected from the group consisting of calcium carbonate, calcium oxide and calcium hydroxide; (b) initiating a reaction by admixing stoichiometric quantities of lactic acid and water with said citric acid and calcium compound of step (a); (c) mixing the reactance of step (b) to produce a dense, hydrated mixture comprising calcium ions, citrate ions and lactate ions in a ratio of about 2:1:1; and (d) dehyrating the dense, hydrated mixture of step (c).
摘要翻译：本发明的一个方面包括具有下式的新化合物：Ca2（OOC-CH2-COHCOO-CH2COO）（CH3CHOH-COO）在本发明的另一方面，提供了一种治疗钙相关病理学的方法。本发明的方法包括提供药学上可接受的组合物的步骤，其包括作为活性成分的柠檬酸二钙 - 乳酸盐化合物，以及向有需要的个体施用治疗有效量的所述药学上可接受的组合物。在本发明的另一方面，提供了一种制备柠檬酸二钙柠檬酸酯化合物的方法。本发明的方法包括以下步骤：（a）混合化学计量的柠檬酸和选自碳酸钙，氧化钙和氢氧化钙的钙化合物; （b）通过将化学计量的乳酸和水与步骤（a）的所述柠檬酸和钙化合物混合来引发反应; （c）将步骤（b）的电抗混合以产生约2:1:1比例的钙离子，柠檬酸根离子和乳酸盐离子的致密的水合混合物; 和（d）使步骤（c）的致密，水合的混合物脱氢。

9. 发明授权

US4904478A Slow-release sodium fluoride tablet and method for treatment of osteoporosis 失效
标题翻译：缓释氟化钠片及治疗骨质疏松症的方法
公开(公告)号：US4904478A
公开(公告)日：1990-02-27
申请号：US112202
申请日：1987-10-22
申请人： Neill B. Walsdorf , Charles Y. C. Pak
发明人： Neill B. Walsdorf , Charles Y. C. Pak
IPC分类号： A61K9/20 , A61K33/16
CPC分类号： A61K33/16 , A61K9/2013
摘要： A novel slow-release sodium fluoride preparation and its use. Such slow-release sodium preparation comprises carnauba wax and talc and may be used to provide a safe but effective level of fluoride in serum, optimal for the treatment of osteoporosis. Gastrointestinal side effects are minimized by limiting the amount of fluoride released in the stomach and rheumatic complications are reduced by avoiding toxic levels of fluoride is serum. The amount of fluoride absorbed is nevertheless sufficient to stimulate bone formation and prevent fractures. Thus, the maintenance of serum fluoride as encompassed in this invention, allows for a safe and effective treatment of osteoporosis.
摘要翻译：一种新型缓释氟化钠制剂及其用途。这种缓释钠制剂包含巴西棕榈蜡和滑石，并且可用于提供血清中安全但有效的氟化物水平，对于治疗骨质疏松症是最佳的。通过限制在胃中释放的氟化物的量来减少胃肠道副作用，并通过避免氟化物是血清的毒性水平来降低风湿并发症。然而，吸收的氟化物的量足以刺激骨形成并防止骨折。因此，维持本发明所包含的血清氟化物，可以安全有效地治疗骨质疏松症。

10. 发明授权

US4888182A Compositions and methods of treating calcium renal stones 失效
标题翻译：治疗钙肾结石的组成和方法
公开(公告)号：US4888182A
公开(公告)日：1989-12-19
申请号：US019056
申请日：1987-02-26
申请人： Charles Y. C. Pak
发明人： Charles Y. C. Pak
IPC分类号： A61K31/19
CPC分类号： A61K31/19 , Y10S514/891
摘要： Methods and compositions useful for the treatment and prophylaxis of calcium renal stones are disclosed. The methods involve administering potassium citrate compositions to persons afflicted with or susceptible to calcium renal stone formations. A typical dosage scheme involves administering about 30 to 120 meq potassium citrate per day in divided doses. Such treatments are effective in dissolving existing calcium stones and preventing formation of new calcium stones. Moreover, the results of a comparative clinical assay indicate the potassium citrate is superior to sodium citrate in the treatment of uric acid lithiasis. Potassium citrate therapy averts calcium renal stone formation, a complication which is often associated with sodium citrate or sodium bicarbonate alkalinization therapy.
摘要翻译：公开了用于治疗和预防钙肾结石的方法和组合物。所述方法涉及将柠檬酸钾组合物施用于患有钙敏感性肾结石形成的患者或易受影响的人。典型的剂量方案包括每天以分剂量施用约30至120毫克柠檬酸钾。这种治疗有效地溶解现有的钙结石并防止形成新的钙结石。此外，比较临床检验的结果表明柠檬酸钾在治疗尿酸结石时优于柠檬酸钠。柠檬酸钾治疗可以避免钙肾结石形成，这种并发症通常与柠檬酸钠或碳酸氢钠碱化治疗相关。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式